Page content
Contact details
Gabriel Sanfélix-Gimeno
Main
Publications
Data source publications
Studies
List of studies that have been conducted using the data source
- A post-authorisation/post-marketing observational study to evaluate the association between exposure to AZD1222 and safety concerns using existing secondary health data sources (COVID-19)
- An Observational Post-Authorization Safety Study to Assess the Safety of Ad26.COV2.S Using European Healthcare Data through VAC4EU (COVID-19)
- Strengthening Use of Real-World Data in Medicines Development: Metadata for Data Discoverability and Study Replicability (MINERVA)
- mRNA-1273-P910: Clinical course, outcomes and risk factors of myocarditis and pericarditis following administration of Moderna vaccines targeting SARS-CoV-2.
- SAFETY-VAC: Network of Data Sources for Vaccine Safety Evaluation
- ADEPT: The utilisation of antiseizure medications in pregnant women, other women of childbearing potential, and men: a multi-database study from 7 European countries
- SAFETY-VAC: Background incidence estimation of flares of pre-existing chronic diseases using pan-European electronic healthcare data sources. (SAFETY VAC)
- DARWIN EU® - CGRP antagonists - Treatment patterns and users characteristics
- ADEPT: feasibility of estimating the risk of adverse pregnancy, neonatal and child outcomes following either in utero ASM exposure through the mother, or peri-conceptional ASM exposure through the father
- SAFETY-VAC: Phenotype proposal and rates of immunocompromised populations in real-world data sources.
- DARWIN EU® - Incidence of suicidality in patients with specific chronic skin conditions
- VAC4EU Postauthorisation Safety Study of BIMERVAX® Vaccine in Europe
- VAC4EU Postauthorisation Effectiveness Study of BIMERVAX® Vaccine in Europe
- A Post-Authorisation Safety Study (PASS) of ABRYSVO (Respiratory Syncytial Virus Stabilised Prefusion Subunit Vaccine) in Pregnant Women and their Offspring in a Real World Setting in Europe and UK
- A post-authorisation safety study of ABRYSVO in immunocompromised, or renally or hepatically impaired adults aged 60 years and older in a real world setting in Europe and UK
- DARWIN EU® - Characterising the use of JAK inhibitors in Europe: a Drug Utilisation Study